186 related articles for article (PubMed ID: 31202735)
21. Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
Elshafae SM; Hassan BB; Supsavhad W; Dirksen WP; Camiener RY; Ding H; Tweedle MF; Rosol TJ
Prostate; 2016 Jun; 76(9):796-809. PubMed ID: 26939805
[TBL] [Abstract][Full Text] [Related]
22. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Finetti F; Terzuoli E; Giachetti A; Santi R; Villari D; Hanaka H; Radmark O; Ziche M; Donnini S
Endocr Relat Cancer; 2015 Aug; 22(4):665-78. PubMed ID: 26113609
[TBL] [Abstract][Full Text] [Related]
23. AKT/GSK-3β regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells.
Liu ZC; Wang HS; Zhang G; Liu H; Chen XH; Zhang F; Chen DY; Cai SH; Du J
Biochim Biophys Acta; 2014 Oct; 1840(10):3096-105. PubMed ID: 25088797
[TBL] [Abstract][Full Text] [Related]
24. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
25. Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in ERK-responsive lung cancer.
Cheng CW; Chen PM; Hsieh YH; Weng CC; Chang CW; Yao CC; Hu LY; Wu PE; Shen CY
Oncotarget; 2015 Dec; 6(42):44222-38. PubMed ID: 26528854
[TBL] [Abstract][Full Text] [Related]
26. SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt/β-catenin pathway.
Li R; Quan Y; Xia W
Exp Cell Res; 2018 Mar; 364(2):143-151. PubMed ID: 29421536
[TBL] [Abstract][Full Text] [Related]
27. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
28. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
29. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
30. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
[TBL] [Abstract][Full Text] [Related]
31. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
33. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway.
Sun C; Sun L; Jiang K; Gao DM; Kang XN; Wang C; Zhang S; Huang S; Qin X; Li Y; Liu YK
Int J Biochem Cell Biol; 2013 Jun; 45(6):1099-108. PubMed ID: 23474366
[TBL] [Abstract][Full Text] [Related]
34. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
35. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
[TBL] [Abstract][Full Text] [Related]
36. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway.
Lu Z; Zhou R; Kong Y; Wang J; Xia W; Guo J; Liu J; Sun H; Liu K; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2016; 16(5):455-65. PubMed ID: 26638886
[TBL] [Abstract][Full Text] [Related]
37. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
[TBL] [Abstract][Full Text] [Related]
38. MiR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2.
Zhiping C; Shijun T; Linhui W; Yapei W; Lianxi Q; Qiang D
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4835-4843. PubMed ID: 29164579
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
40. Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.
Qi G; Lu G; Yu J; Zhao Y; Wang C; Zhang H; Xia Q
Eur J Pharmacol; 2019 Oct; 860():172551. PubMed ID: 31323225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
